New research demonstrating the clinical utility of Bio-Rad's Droplet Digital PCR (ddPCR) powered liquid biopsy will be presented this week during the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, March 29-April 3. Many of the studies rely on the sensitivity, speed, and cost-effectiveness of ddPCR technology to measure blood-based tumor biomarkers in a reproducible way.
You are here
A remarkable recent increase in the diagnosis of vocal-cord cancer in young adults appears to be the result of infection with strains of human papilloma virus (HPV) that also cause cervical cancer and other malignancies. Investigators from Massachusetts General Hospital (MGH) describe finding HPV infection in all tested samples of vocal-cord cancer from 10 patients diagnosed at age 30 or under, most of whom were non-smokers.
Immune checkpoint inhibitors, such as the anti-PD-1 antibody pembrolizumab, have become important tools for managing non-small-cell lung cancer (NSCLC). Assessing the level of programmed death ligand 1 (PD-L1) expressed by a tumor can help clinicians determine how the patient should be treated. A report in The Journal of Molecular Diagnostics describes a novel and rapid approach for quantifying PD-L1 expression levels in tumors that requires only small amounts of tissue that can be collected using minimally-invasive bronchoscopy techniques.
In low-resource countries without well-developed screening programs, expanding access to human papilloma virus (HPV) vaccination is the best means of preventing cervical cancer and other diseases caused by HPV infection, according to an editorial in the October special issue of the Journal of Lower Genital Tract Disease, official journal of ASCCP. The journal is published in the Lippincott portfolio by Wolters Kluwer.
Inhibiting the Jagged 1 protein in mice prevents the proliferation and growth of colon and rectal tumors. What is more, this approach to the disease permits the removal of existing tumors.
In a "proof of concept" study, scientists at Johns Hopkins Medicine say they have successfully delivered nano-size packets of genetic code called microRNAs to treat human brain tumors implanted in mice. The contents of the super-small containers were designed to target cancer stem cells, a kind of cellular "seed" that produces countless progeny and is a relentless barrier to ridding the brain of malignant cells.
Results of their experiments were published online June 21 in Nano Letters.
A study in Molecular Oncology indicates that examining the protein and RNA in leftover materials from routine diagnostic tests for breast cancer may lead to more accurate diagnoses.
Using samples from fine needle aspiration from 25 patients with breast cancer and 33 patients with benign lesions, investigators found that such a strategy could distinguish all cancer patient samples from all benign lesions.
A Loyola Medicine study has found that new ultrasound guidelines can reliably identify pediatric patients who should be biopsied for thyroid cancer.
The study by radiologist Jennifer Lim-Dunham, MD, and colleagues was presented May 18 during the Society for Pediatric Radiology's annual meeting in Nashville.
Thyroid cancer is a common cause of cancer in teenagers, and the incidence is increasing for reasons that are unclear. Adolescents have a 10-fold greater incidence than younger children, and the disease is five times more common in girls than boys.
Please give an overview of the past research into machine learning and artificial intelligence in medical imaging. What are we currently able to do with this research?
The two major tasks in medical imaging that appear to be naturally predestined to be solved with AI algorithms are segmentation and classification. Most of techniques used in medical imaging were conventional image processing, or more widely formulated computer vision algorithms.
Multiple SelectMDx Clinical Study Abstracts presented at 2018 Global Prostate Congress in Frankfurt, Germany
MDxHealth SA, today announced the publication of positive data demonstrating the value of the SelectMDx liquid biopsy test for Prostate Cancer in guiding patient management for men being considered for multiparametric MRI and the clinical utility in guiding biopsy decisions in real-world clinical practice. Data will be presented at the sixth Global Congress on Prostate Cancer (PROSCA) in Frankfurt, Germany, June 28-30, 2018.